{"id":56001,"date":"2023-04-19T15:04:12","date_gmt":"2023-04-19T13:04:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wugen-presents-new-preclinical-data-reinforcing-anti-tumor-functionality-of-wu-nk-101-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/"},"modified":"2023-04-19T15:04:12","modified_gmt":"2023-04-19T13:04:12","slug":"wugen-presents-new-preclinical-data-reinforcing-anti-tumor-functionality-of-wu-nk-101-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wugen-presents-new-preclinical-data-reinforcing-anti-tumor-functionality-of-wu-nk-101-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/","title":{"rendered":"Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023"},"content":{"rendered":"
\n

\n— Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) —<\/i><\/p>\n

\n— WU-NK-101 demonstrated PD-L1 and MHC-I checkpoint upregulation in solid tumor models —<\/i><\/p>\n

\n— Data highlight the potential of <\/i>WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance<\/i> —<\/i><\/p>\n

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc.<\/a>, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented data on WU-NK-101, the company\u2019s lead memory natural killer (NK) cell therapy product, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida from April 14 \u2013 19, 2023.<\/p>\n

<\/a><\/p>\n

\n\u201cThese data build on the growing body of evidence demonstrating the broad, powerful immuno-oncological applications of WU-NK-101,\u201d said Kumar Srinivasan, Ph.D., M.B.A., President and Chief Executive Officer of Wugen. \u201cIn addition to our ongoing efforts to advance WU-NK-101 for AML and colorectal cancer, we plan to explore WU-NK-101 as a salvage therapy for patients who have failed or are resistant to immune checkpoint blockade treatment, given the tremendous need and lack of options in this population.\u201d<\/p>\n

\n\u201cWU-NK-101 has a unique phenotype that supports enhanced cytotoxicity, metabolic fitness and flexibility, and resistance to immunosuppression within the TME,\u201d added Sergio Rutella, M.D., Ph.D., FRCPath, FRSB, Professor of Cancer Immunotherapy at Nottingham Trent University, and a co-author of the study. \u201cToday\u2019s findings further enhance WU-NK-101\u2019s anti-tumor profile, showing that these cells can also enhance the adaptive immune response in the TME, upregulate key checkpoints, and potentially increase cytotoxicity in combination with checkpoint inhibitors. These findings are extremely promising and suggest a synergistic effect when combining WU-NK-101 with CPI antibodies to treat solid tumors.\u201d<\/p>\n

\nToday\u2019s presentation highlighted the following:<\/p>\n